{"id":"https://openalex.org/W2203365682","doi":null,"title":"The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.","display_name":"The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.","publication_year":2012,"publication_date":"2012-02-01","ids":{"openalex":"https://openalex.org/W2203365682","mag":"2203365682","pmid":"https://pubmed.ncbi.nlm.nih.gov/22287733"},"language":"en","primary_location":{"id":"pmid:22287733","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22287733","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anticancer research","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063844606","display_name":"Catrin Schult","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4665924","display_name":"University of Rostock","ror":"https://ror.org/03zdwsf69","country_code":"DE","type":"education","lineage":["https://openalex.org/I4665924"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Catrin Schult","raw_affiliation_strings":["University of Rostock, Division of Medicine, Department of Hematology, Oncology and Palliative Medicine, Ernst Heydemann Str. 6, 18057 Rostock, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Rostock, Division of Medicine, Department of Hematology, Oncology and Palliative Medicine, Ernst Heydemann Str. 6, 18057 Rostock, Germany","institution_ids":["https://openalex.org/I4665924"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111856863","display_name":"Meike Dahlhaus","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Meike Dahlhaus","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090917913","display_name":"\u00c4enne Glass","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Aenne Glass","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103106970","display_name":"Kristin J. Fischer","orcid":"https://orcid.org/0000-0003-2046-0736","observed_orcids":["https://orcid.org/0000-0003-2046-0736","https://orcid.org/0000-0001-8235-4942","https://orcid.org/0000-0002-8272-6037"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kristin Fischer","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074270747","display_name":"Sandra Lange","orcid":"https://orcid.org/0000-0003-0725-3652","observed_orcids":["https://orcid.org/0000-0003-0725-3652"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sandra Lange","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109092416","display_name":"Mathias Freund","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mathias Freund","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5087351196","display_name":"Christian Junghan\u00df","orcid":"https://orcid.org/0000-0003-4707-777X","observed_orcids":["https://orcid.org/0000-0003-4707-777X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christian Junghanss","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.8844,"has_fulltext":false,"cited_by_count":49,"citation_normalized_percentile":{"value":0.94181121,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"32","issue":"2","first_page":"463","last_page":"74"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.6801999807357788,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.6801999807357788,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.31470000743865967,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nvp-bez235","display_name":"NVP-BEZ235","score":0.9990000128746033},{"id":"https://openalex.org/keywords/dual-pi3k-mtor-inhibitor","display_name":"PI3K/mTOR dual inhibitor","score":0.703000009059906},{"id":"https://openalex.org/keywords/acute-lymphoblastic-leukemia","display_name":"acute lymphoblastic leukemia","score":1.0},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.765999972820282},{"id":"https://openalex.org/keywords/cytarabine","display_name":"cytarabine","score":0.9879999756813049},{"id":"https://openalex.org/keywords/doxorubicin","display_name":"doxorubicin","score":1.0},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":0.9990000128746033},{"id":"https://openalex.org/keywords/glucocorticoid-resistance","display_name":"glucocorticoid resistance","score":0.7879999876022339},{"id":"https://openalex.org/keywords/g0-g1-cell-cycle-arrest","display_name":"G0/G1 cell cycle arrest","score":0.8989999890327454},{"id":"https://openalex.org/keywords/cdk4","display_name":"CDK4","score":0.8389999866485596},{"id":"https://openalex.org/keywords/cyclin-d3","display_name":"cyclin D3","score":0.9990000128746033},{"id":"https://openalex.org/keywords/antiproliferative-activity","display_name":"antiproliferative activity","score":0.8799999952316284},{"id":"https://openalex.org/keywords/synergistic-cytotoxicity","display_name":"synergistic cytotoxicity","score":0.7440000176429749}],"concepts":[{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5663619041442871},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.5636317729949951},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5348621010780334},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.49166589975357056},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.47462761402130127},{"id":"https://openalex.org/C2781303535","wikidata":"https://www.wikidata.org/wiki/Q18936","display_name":"Doxorubicin","level":3,"score":0.4455910325050354},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.414858341217041},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.36295485496520996},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.30685150623321533},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.27549293637275696},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.274612158536911},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.26726940274238586},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.09784722328186035}],"mesh":[{"descriptor_ui":"D000081082","descriptor_name":"Phosphoinositide-3 Kinase Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D003561","descriptor_name":"Cytarabine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003907","descriptor_name":"Dexamethasone","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004357","descriptor_name":"Drug Synergism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011804","descriptor_name":"Quinolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011804","descriptor_name":"Quinolines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015448","descriptor_name":"Leukemia, B-Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D015448","descriptor_name":"Leukemia, B-Cell","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D015448","descriptor_name":"Leukemia, B-Cell","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D015448","descriptor_name":"Leukemia, B-Cell","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019169","descriptor_name":"Jurkat Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D048708","descriptor_name":"Cell Growth Processes","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D051058","descriptor_name":"Oncogene Protein v-akt","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D051058","descriptor_name":"Oncogene Protein v-akt","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D054198","descriptor_name":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D054198","descriptor_name":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D054198","descriptor_name":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D054218","descriptor_name":"Precursor T-Cell Lymphoblastic Leukemia-Lymphoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D054218","descriptor_name":"Precursor T-Cell Lymphoblastic Leukemia-Lymphoma","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D054218","descriptor_name":"Precursor T-Cell Lymphoblastic Leukemia-Lymphoma","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D054218","descriptor_name":"Precursor T-Cell Lymphoblastic Leukemia-Lymphoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D058539","descriptor_name":"Phosphatidylinositol 3-Kinase","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D058570","descriptor_name":"TOR Serine-Threonine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D058570","descriptor_name":"TOR Serine-Threonine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D059447","descriptor_name":"Cell Cycle Checkpoints","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:22287733","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22287733","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anticancer research","raw_type":"Journal Article"},{"id":"mag:2203365682","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22287733","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":49,"referenced_works":["https://openalex.org/W1701044074","https://openalex.org/W1963747895","https://openalex.org/W1966368595","https://openalex.org/W1974756622","https://openalex.org/W1975317091","https://openalex.org/W1977613401","https://openalex.org/W1986943079","https://openalex.org/W1988377311","https://openalex.org/W1999198216","https://openalex.org/W2000731858","https://openalex.org/W2004691500","https://openalex.org/W2005002555","https://openalex.org/W2009348015","https://openalex.org/W2013036515","https://openalex.org/W2019308110","https://openalex.org/W2021012077","https://openalex.org/W2023660529","https://openalex.org/W2037600362","https://openalex.org/W2038620630","https://openalex.org/W2039628288","https://openalex.org/W2042676899","https://openalex.org/W2049396238","https://openalex.org/W2060737851","https://openalex.org/W2065322400","https://openalex.org/W2069228161","https://openalex.org/W2069906998","https://openalex.org/W2070308429","https://openalex.org/W2071394735","https://openalex.org/W2082935538","https://openalex.org/W2084507055","https://openalex.org/W2087090648","https://openalex.org/W2087598047","https://openalex.org/W2087861588","https://openalex.org/W2101967561","https://openalex.org/W2107612707","https://openalex.org/W2111065680","https://openalex.org/W2117028091","https://openalex.org/W2118754985","https://openalex.org/W2118995216","https://openalex.org/W2123781894","https://openalex.org/W2125657361","https://openalex.org/W2128396288","https://openalex.org/W2131888987","https://openalex.org/W2132033628","https://openalex.org/W2144724291","https://openalex.org/W2148848488","https://openalex.org/W2157983986","https://openalex.org/W2158226650","https://openalex.org/W2158305336"],"related_works":["https://openalex.org/W2558830983","https://openalex.org/W2118754985","https://openalex.org/W2582039583","https://openalex.org/W2571886330","https://openalex.org/W1701902327","https://openalex.org/W2979818067","https://openalex.org/W2587670985","https://openalex.org/W1581950988","https://openalex.org/W2980257051","https://openalex.org/W1995831059"],"abstract_inverted_index":{"BACKGROUND:":[0],"Inhibition":[1,111],"of":[2,21,39,90,103,112,162],"signal":[3],"transduction":[4],"pathways":[5],"has":[6,26],"been":[7],"successfully":[8],"introduced":[9],"into":[10],"cancer":[11],"treatment.":[12],"The":[13],"dual":[14],"phosphatidylinositol":[15],"3-kinase":[16],"(PI3K)":[17],"and":[18,47,63,87,100,108,114,121,152],"mammalian":[19],"target":[20],"rapamycin":[22],"(mTOR)":[23],"inhibitor":[24],"NVP-BEZ235":[25,40,68,82,124,144],"antitumor":[27],"activity":[28,38,89,116],"in":[29,41,71,140,149,159],"vitro":[30],"against":[31],"solid":[32],"tumors.":[33],"Here,":[34],"we":[35],"examined":[36],"the":[37,48,85,133,160],"acute":[42],"lymphoblastic":[43],"leukemia":[44],"(ALL)":[45],"cells":[46,151],"best":[49],"modalities":[50],"for":[51],"combination":[52,72],"approaches.":[53],"MATERIALS":[54],"AND":[55],"METHODS:":[56],"ALL":[57,91,150],"cell":[58],"lines":[59],"(SEM,":[60],"RS4;11,":[61],"Jurkat":[62],"MOLT4)":[64],"were":[65,95],"treated":[66],"with":[67,73,97,126],"alone,":[69],"or":[70,78,129],"cytarabine":[74],"(AraC),":[75],"doxorubicin":[76],"(Doxo)":[77],"dexamethasone":[79],"(Dexa).":[80],"RESULTS:":[81],"potently":[83],"inhibited":[84],"proliferation":[86],"metabolic":[88],"cells.":[92,142],"Antiproliferative":[93],"effects":[94,148],"associated":[96],"G(0)/G(1)":[98],"arrest":[99],"reduced":[101],"levels":[102],"cyclin-dependent":[104],"kinase":[105],"4":[106],"(CDK4)":[107],"cyclin":[109],"D3.":[110],"PI3K":[113],"mTOR":[115],"was":[117],"detected":[118],"at":[119],"10":[120],"100":[122],"nM.":[123],"combined":[125],"AraC,":[127],"Doxo":[128],"Dexa":[130],"synergistically":[131],"enhanced":[132],"cytotoxicity":[134],"compared":[135],"to":[136],"single-drug":[137],"treatment,":[138],"even":[139],"glucocorticoid-resistant":[141],"CONCLUSION:":[143],"displays":[145],"pronounced":[146],"antiproliferative":[147],"might":[153],"therefore":[154],"be":[155],"a":[156],"useful":[157],"drug":[158],"treatment":[161],"ALL.":[163]},"counts_by_year":[{"year":2024,"cited_by_count":3},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}